Correlation of C-Met Expression and Outcome in Patients With Renal Cell Carcinoma Treated With Sunitinib

Clinical Genitourinary Cancer - United States
doi 10.1016/j.clgc.2017.01.021
Full Text
Abstract

Available in full text

Categories
OncologyUrology
Date
Authors
Publisher

Elsevier BV

Related search

Sunitinib Causes Macrocytosis in Patients With Advanced Renal Cell Carcinoma

Current Oncology
Oncology
2010English

Reversible Myocardial Dysfunction in a Young Woman With Metastatic Renal Cell Carcinoma Treated With Sunitinib

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2009English

Hypertension as Predictor of Sunitinib Treatment Outcome in Metastatic Renal Cell Carcinoma

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2011English

A Case of Metastatic Renal Cell Carcinoma and Bile Duct Carcinoma Treated With a Combination of Sunitinib and Gemcitabine

BMC Cancer
Cancer ResearchOncologyGenetics
2015English

A Phase 2 Trial of Sunitinib in Patients With Advanced Non–clear Cell Renal Cell Carcinoma

European Urology
Urology
2012English

Mp16-01 Clinical Implications of Sunitinib and N-Desethyl-Sunitinib Plasma Concentrations for Treatment Outcome in Metastatic Renal Cell Carcinoma Patients

Journal of Urology
Urology
2017English

Gender-Related Differences in Surgically Treated Patients With Renal Cell Carcinoma

Journal of Urological Surgery
2018English

Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial

Oncologist
Cancer ResearchMedicineOncology
2015English

Genetic Polymorphisms Associated With a Prolonged Progression-Free Survival in Patients With Metastatic Renal Cell Cancer Treated With Sunitinib

Clinical Cancer Research
Cancer ResearchOncology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy